Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Genome Sciences to Evaluate Bayer Diagnostics Breast Cancer Biomarkers

NEW YORK, March 16 (GenomeWeb News) -Oxford Genome Sciences will use its proteomics platform and its Oxford Genome Anatomy Project to evaluate biomarkers linked to breast cancer for Bayer HealthCare's diagnostics division, the companies said today.


Though financial terms of the agreement were not disclosed, Bayer said it "has committed program funding" to Oxford, and agreed to performance-related payments upon achieving certain milestones.

Bayer HealthCare hopes this research will help it discover and develop therapeutic and diagnostic products for breast cancer. 

According to Oxford, the OGAP proteomics database has more than 1 million peptide sequences from approximately 50 different tissues involved in almost 60 different diseases mapped onto 15,000 human genes.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.